Core Scientific (CORZ) director receives 18,575-share RSU grant

Rhea-AI Filing Summary

Core Scientific director Eric Stanton Weiss received a new equity grant. On February 4, 2026, he was awarded 18,575 shares of Core Scientific common stock at a price of $0 per share, bringing his directly held stake to 245,262 shares.

The award is structured as restricted stock units that will vest in full on February 3, 2027, provided Weiss continues to serve the company as a non-employee director through that date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weiss Eric Stanton

(Last) (First) (Middle)

C/O CORE SCIENTIFIC, INC.

838 WALKER ROAD, SUITE 21-2105

(Street)

DOVER DE 19904

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Core Scientific, Inc./tx [ CORZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/04/2026		A		18,575(1)	A	$0	245,262	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant. The RSUs will vest in full on February 3, 2027, provided that the Reporting Person continues to provide service to the Issuer as a non-employee director on such date.

	/s/ Todd DuChene, as Attorney-in-Fact	02/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Core Scientific (CORZ) report for Eric Stanton Weiss?

Core Scientific reported that director Eric Stanton Weiss received 18,575 shares of common stock on February 4, 2026. The shares were granted at a price of $0 per share as a restricted stock unit award, increasing his directly held position to 245,262 shares.

How many Core Scientific shares does Eric Stanton Weiss own after this Form 4 transaction?

After the reported transaction, Eric Stanton Weiss beneficially owns 245,262 shares of Core Scientific common stock directly. This figure includes the newly granted 18,575 restricted stock units and reflects his holdings following the February 4, 2026 equity award.

What are the vesting terms of Eric Stanton Weiss’s Core Scientific RSU grant?

The restricted stock unit grant to Eric Stanton Weiss vests in full on February 3, 2027. Vesting is contingent on his continued service to Core Scientific as a non-employee director through that date, aligning the award with his ongoing board role.

What was the price per share for Eric Stanton Weiss’s Core Scientific equity grant?

The 18,575-share equity grant to Eric Stanton Weiss was issued at a price of $0 per share. This reflects a typical restricted stock unit structure, where shares are granted without purchase cost but are subject to future vesting conditions and service requirements.

What role does Eric Stanton Weiss hold at Core Scientific in this Form 4?

In this filing, Eric Stanton Weiss is identified as a director of Core Scientific and not an officer or 10% owner. The RSU grant is tied to his position as a non-employee director, with continued board service required for the award to vest.